Hulio

Hulio is a prescription biologic medication whose active ingredient is adalimumab, a TNF‑alpha inhibitor delivered as a subcutaneous injection. It is marketed in the European Union and is classified as a biologic disease‑modifying antirheumatic drug (bDMARD). The product is supplied in pre‑filled syringes (strength not specified) for self‑administration under medical supervision.

Hulio is indicated for several chronic inflammatory conditions that respond to TNF‑alpha blockade. It is used when conventional therapies have not achieved adequate disease control.

- Rheumatoid arthritis in adults - Psoriatic arthritis and plaque psoriasis - Ankylosing spondylitis - Moderate to severe Crohn's disease - Ulcerative colitis - Hidradenitis suppurativa

Adalimumab may cause a range of adverse reactions, from mild to severe. Patients should be informed about the most frequently observed events as well as those that require urgent medical attention.

Common: - Injection‑site pain, redness, or swelling - Upper respiratory tract infections - Headache - Nausea - Mild rash or itching

Serious: - Serious infections (e.g., tuberculosis, fungal infections) - Reactivation of hepatitis B - Malignancies such as lymphoma - Severe allergic reactions (anaphylaxis) - Neurological disorders (e.g., demyelinating disease)

Before starting Hulio, clinicians should evaluate patient history and monitor for potential complications throughout therapy.

- Screen for latent tuberculosis and hepatitis B infection - Assess for active infections; defer treatment if present - Evaluate for a history of malignancy or demyelinating disease - Use caution in patients with congestive heart failure - Monitor complete blood counts and liver function periodically - Discuss vaccination status; avoid live vaccines during treatment

Adalimumab can influence the activity of other medicines, and some agents may affect its safety profile.

Avoid: - Live attenuated vaccines (e.g., measles, varicella) - Concurrent use of other biologic immunosuppressants without specialist guidance

Use with caution: - Systemic corticosteroids and other immunosuppressants (e.g., methotrexate) - Antifungal agents (e.g., azoles) - Antiviral therapies for hepatitis B - Drugs that prolong QT interval (monitor cardiac status) - Vaccines containing inactivated organisms (administer before starting therapy)